And yet the NIH does not feel a new class of antibiotic, namely Brilacidin, that works differently and makes resistance extremely unlikely to be developed by bacteria is not worthy of a grant to get a P3 trial conducted?
They sponsor so many gobblygook ideas and yet make one of the largest threats to the human race go unchecked.
Aculeus, on its face this looks great for B for absssi. But its use is only for skin infections, not systemic infections. I never understood why, given the vast need for more MDR drugs, B was not directed to pill form to also address systemic infections. Never got a satisfactory answer though I have plowed through lots of articles and posters and never got anything approaching an answer.
News 
Market Data 
Discover 
AI
